---
document_datetime: 2025-06-19 14:13:18
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pazenir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pazenir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6015124
conversion_datetime: 2025-12-27 17:08:14.392798
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pazenir

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 19/06/2025                          |                                             | SmPC, Annex                      | To update section 4.6 of the SmPC based on the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000278406   | II, Labelling and PL   | Reproductive Toxicity Testing and Labeling recommendations, Food and Drug Administration Guidance (May 2019) and the Non-clinical Working Party/Non-clinical Working Party (S/Nc), European Medicines Agency recommendations (March 2023) on the duration of contraception following the end of treatment with a genotoxic drug. The Package Leaflet is updated accordingly. The changes follow assessment of the same changes for the reference   |
|---------------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000235953   | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.c Deletion of a non-significant in-process test - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted   | 05/12/2024   | N/A   |                                  |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------------------------|
| Variation type IA / EMA/VR/0000221290   | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                 | 29/08/2024   |       | SmPC, Annex II, Labelling and PL |